The Effect of DLBS1449 in Diabetic Patients With Low HDL-Cholesterol - Double Blind Comparative Study With Placebo

Trial Profile

The Effect of DLBS1449 in Diabetic Patients With Low HDL-Cholesterol - Double Blind Comparative Study With Placebo

Withdrawn prior to enrolment
Phase of Trial: Phase II/III

Latest Information Update: 08 Aug 2016

At a glance

  • Drugs DLBS 1449 (Primary)
  • Indications Dyslipidaemias
  • Focus Therapeutic Use
  • Sponsors Dexa Medica
  • Most Recent Events

    • 03 Aug 2016 Status changed from not yet recruiting to withdrawn prior to enrolment.
    • 11 Feb 2016 Planned End Date changed from 1 Jul 2017 to 1 Jan 2018 as reported by ClinicalTrials.gov record.
    • 11 Feb 2016 Planned primary completion date changed from 1 Apr 2017 to 1 Oct 2017 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top